A dominant-negative isoform of IKAROS expands primitive normal human hematopoietic cells

Philip A. Beer, David J.H.F. Knapp, Nagarajan Kannan, Paul H. Miller, Sonja Babovic, Elizabeth Bulaeva, Nima Aghaeepour, Gabrielle Rabu, Shabnam Rostamirad, Kingsley Shih, Lisa Wei, Connie J. Eaves

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Disrupted IKAROS activity is a recurrent feature of some human leukemias, but effects on normal human hematopoietic cells are largely unknown. Here, we used lentivirally mediated expression of a dominant-negative isoform of IKAROS (IK6) to block normal IKAROS activity in primitive human cord blood cells and their progeny. This produced a marked (10-fold) increase in serially transplantable multipotent IK6+ cells as well as increased outputs of normally differentiating B cells and granulocytes in transplanted immunodeficient mice, without producing leukemia. Accompanying T/natural killer (NK) cell outputs were unaltered, and erythroid and platelet production was reduced. Mechanistically, IK6 specifically increased human granulopoietic progenitor sensitivity to two growth factors and activated CREB and its targets (c-FOS and Cyclin B1). In more primitive human cells, IK6 prematurely initiated a B cell transcriptional program without affecting the hematopoietic stem cell-associated gene expression profile. Some of these effects were species specific, thus identifying novel roles of IKAROS in regulating normal human hematopoietic cells.

Original languageEnglish (US)
Pages (from-to)841-857
Number of pages17
JournalStem Cell Reports
Volume3
Issue number5
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Protein Isoforms
Cells
Cyclin B1
Leukemia
B-Lymphocytes
Platelets
Stem cells
Gene expression
Intercellular Signaling Peptides and Proteins
Natural Killer T-Cells
Blood
Hematopoietic Stem Cells
Fetal Blood
Transcriptome
Granulocytes
Blood Cells
Blood Platelets

ASJC Scopus subject areas

  • Biochemistry
  • Genetics
  • Developmental Biology
  • Cell Biology

Cite this

Beer, P. A., Knapp, D. J. H. F., Kannan, N., Miller, P. H., Babovic, S., Bulaeva, E., ... Eaves, C. J. (2014). A dominant-negative isoform of IKAROS expands primitive normal human hematopoietic cells. Stem Cell Reports, 3(5), 841-857. https://doi.org/10.1016/j.stemcr.2014.09.006

A dominant-negative isoform of IKAROS expands primitive normal human hematopoietic cells. / Beer, Philip A.; Knapp, David J.H.F.; Kannan, Nagarajan; Miller, Paul H.; Babovic, Sonja; Bulaeva, Elizabeth; Aghaeepour, Nima; Rabu, Gabrielle; Rostamirad, Shabnam; Shih, Kingsley; Wei, Lisa; Eaves, Connie J.

In: Stem Cell Reports, Vol. 3, No. 5, 01.01.2014, p. 841-857.

Research output: Contribution to journalArticle

Beer, PA, Knapp, DJHF, Kannan, N, Miller, PH, Babovic, S, Bulaeva, E, Aghaeepour, N, Rabu, G, Rostamirad, S, Shih, K, Wei, L & Eaves, CJ 2014, 'A dominant-negative isoform of IKAROS expands primitive normal human hematopoietic cells', Stem Cell Reports, vol. 3, no. 5, pp. 841-857. https://doi.org/10.1016/j.stemcr.2014.09.006
Beer, Philip A. ; Knapp, David J.H.F. ; Kannan, Nagarajan ; Miller, Paul H. ; Babovic, Sonja ; Bulaeva, Elizabeth ; Aghaeepour, Nima ; Rabu, Gabrielle ; Rostamirad, Shabnam ; Shih, Kingsley ; Wei, Lisa ; Eaves, Connie J. / A dominant-negative isoform of IKAROS expands primitive normal human hematopoietic cells. In: Stem Cell Reports. 2014 ; Vol. 3, No. 5. pp. 841-857.
@article{61ff8cefcd8649169d0835261ac6dc3d,
title = "A dominant-negative isoform of IKAROS expands primitive normal human hematopoietic cells",
abstract = "Disrupted IKAROS activity is a recurrent feature of some human leukemias, but effects on normal human hematopoietic cells are largely unknown. Here, we used lentivirally mediated expression of a dominant-negative isoform of IKAROS (IK6) to block normal IKAROS activity in primitive human cord blood cells and their progeny. This produced a marked (10-fold) increase in serially transplantable multipotent IK6+ cells as well as increased outputs of normally differentiating B cells and granulocytes in transplanted immunodeficient mice, without producing leukemia. Accompanying T/natural killer (NK) cell outputs were unaltered, and erythroid and platelet production was reduced. Mechanistically, IK6 specifically increased human granulopoietic progenitor sensitivity to two growth factors and activated CREB and its targets (c-FOS and Cyclin B1). In more primitive human cells, IK6 prematurely initiated a B cell transcriptional program without affecting the hematopoietic stem cell-associated gene expression profile. Some of these effects were species specific, thus identifying novel roles of IKAROS in regulating normal human hematopoietic cells.",
author = "Beer, {Philip A.} and Knapp, {David J.H.F.} and Nagarajan Kannan and Miller, {Paul H.} and Sonja Babovic and Elizabeth Bulaeva and Nima Aghaeepour and Gabrielle Rabu and Shabnam Rostamirad and Kingsley Shih and Lisa Wei and Eaves, {Connie J.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.stemcr.2014.09.006",
language = "English (US)",
volume = "3",
pages = "841--857",
journal = "Stem Cell Reports",
issn = "2213-6711",
publisher = "Cell Press",
number = "5",

}

TY - JOUR

T1 - A dominant-negative isoform of IKAROS expands primitive normal human hematopoietic cells

AU - Beer, Philip A.

AU - Knapp, David J.H.F.

AU - Kannan, Nagarajan

AU - Miller, Paul H.

AU - Babovic, Sonja

AU - Bulaeva, Elizabeth

AU - Aghaeepour, Nima

AU - Rabu, Gabrielle

AU - Rostamirad, Shabnam

AU - Shih, Kingsley

AU - Wei, Lisa

AU - Eaves, Connie J.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Disrupted IKAROS activity is a recurrent feature of some human leukemias, but effects on normal human hematopoietic cells are largely unknown. Here, we used lentivirally mediated expression of a dominant-negative isoform of IKAROS (IK6) to block normal IKAROS activity in primitive human cord blood cells and their progeny. This produced a marked (10-fold) increase in serially transplantable multipotent IK6+ cells as well as increased outputs of normally differentiating B cells and granulocytes in transplanted immunodeficient mice, without producing leukemia. Accompanying T/natural killer (NK) cell outputs were unaltered, and erythroid and platelet production was reduced. Mechanistically, IK6 specifically increased human granulopoietic progenitor sensitivity to two growth factors and activated CREB and its targets (c-FOS and Cyclin B1). In more primitive human cells, IK6 prematurely initiated a B cell transcriptional program without affecting the hematopoietic stem cell-associated gene expression profile. Some of these effects were species specific, thus identifying novel roles of IKAROS in regulating normal human hematopoietic cells.

AB - Disrupted IKAROS activity is a recurrent feature of some human leukemias, but effects on normal human hematopoietic cells are largely unknown. Here, we used lentivirally mediated expression of a dominant-negative isoform of IKAROS (IK6) to block normal IKAROS activity in primitive human cord blood cells and their progeny. This produced a marked (10-fold) increase in serially transplantable multipotent IK6+ cells as well as increased outputs of normally differentiating B cells and granulocytes in transplanted immunodeficient mice, without producing leukemia. Accompanying T/natural killer (NK) cell outputs were unaltered, and erythroid and platelet production was reduced. Mechanistically, IK6 specifically increased human granulopoietic progenitor sensitivity to two growth factors and activated CREB and its targets (c-FOS and Cyclin B1). In more primitive human cells, IK6 prematurely initiated a B cell transcriptional program without affecting the hematopoietic stem cell-associated gene expression profile. Some of these effects were species specific, thus identifying novel roles of IKAROS in regulating normal human hematopoietic cells.

UR - http://www.scopus.com/inward/record.url?scp=84922605057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922605057&partnerID=8YFLogxK

U2 - 10.1016/j.stemcr.2014.09.006

DO - 10.1016/j.stemcr.2014.09.006

M3 - Article

VL - 3

SP - 841

EP - 857

JO - Stem Cell Reports

JF - Stem Cell Reports

SN - 2213-6711

IS - 5

ER -